Get Newsletter
AlzRisk Paper Detail
Back

Reference: Beydoun, 2011
Cohort: Baltimore Longitudinal Study of Aging
Risk Factor: Statin use


Average Follow-up Time Detail
The median follow-up time for the original cohort was 24.9 years. The article does not provide the mean follow-up time for participants included in this analysis.

Exposure Detail
The investigators ascertained the exposure information by taking an inventory of all over-the-counter and prescription medication in current use at each visit.

The investigators compared incident AD risk in two groups:
the group of participants who ever used statins beyond 50 years of age and before the onset of dementia or mild cognitive impairment (MCI) ("Ever used") and the reference group of participants who never used statins, or if they used them only at or prior to age 50, or only at or after the onset of dementia or MCI ("Never used").

Screening and Diagnosis Detail
Screening Method:
BlessedBlessed Information-Memory-Concentration Test
CDRClinical Dementia Rating (Berg 1988) (CDR)
DQDementia Questionnaire (Silverman 1986)

AD Diagnosis:
DSM IIIR Diagnostic and Statistical Manual III-Revised
NINCDS ADRDA National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association Criteria (McKhann 1984)

Total dementia definition: Dementia via DSM-IIIR

Covariates & Analysis Detail
Analysis Type:
Cox proportional hazards regression

AD Covariates:
Aage
Eeducation
Ggender
BMIbody mass index
CVDcardiovascular disease
DLMdyslipidemia
HTNhypertension
RErace/ethnicity
SMsmoking status
SBPsystolic blood pressure
§ Covariates for total dementia are different.

TD Covariates:
Aage
Eeducation
Ggender
BMIbody mass index
CVDcardiovascular disease
DLMdyslipedemia
HTNhypertension
RErace/ethnicity
SMsmoking status
SBPsystolic blood pressure